Pancreatic Cancer Research

ResearcherNorth Sichuan Medical UniversityNo recent work listed

Bo Mu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-3561-2002; OpenAlex author ID A5054397448. Sources: OpenAlex.

Their work

Papers
4 (first author 0, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
4
Papers, trials and grants by year

2019: 1 paper · 2020: 1 paper · 2021: none · 2022: 1 paper · 2023: 1 paper

Papers 4

  1. Wild‑type KRAS inhibits the migration and invasion of pancreatic cancer through the Wnt/β‑catenin pathway. Co-author DOI 10.3892/mmr.2022.12891↗
  2. Effect of F11R Gene Knockdown on Malignant Biological Behaviors of Pancreatic Cancer Cells. Co-author DOI 10.1155/2022/3379027↗
  3. IL10-modified Human Mesenchymal Stem Cells inhibit Pancreatic Cancer growth through Angiogenesis Inhibition. Last author DOI 10.7150/jca.38062↗
  4. The Role of F11R in Pancreatic Cancer Malignancy and Its Clinical Implication as a Therapeutic Target Last author DOI 10.21203/rs.2.13324/v1↗

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Xianhua Hu · 4 shared papers, 2019–2023 · strength 0.61
  2. Chunyan Zhao · 4 shared papers, 2019–2023 · strength 0.61
  3. Haidi Zhang · 3 shared papers, 2019–2022 · strength 0.38
  4. Yu Pu · 2 shared papers, 2020–2022 · strength 0.27

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.